Introduction
============

Usher syndrome (USH, OMIM 276900, OMIM 276905, OMIM 605472, ORPHA: 886) is the most prevalent deaf-blindness of genetic origin. It is a recessive inherited disease characterized by sensorineural hearing loss (HL), visual loss due to retinitis pigmentosa (RP), and, in some cases, vestibular dysfunction. Prevalence estimates range from 3.2 to 6.2/100,000 ([@B12]; [@B19]).

Patients with USH are classified into three clinical subtypes (USH1, USH2, or USH3), based on the severity and progression of hearing impairment and the presence or absence of vestibular dysfunction. Usher syndrome type I (USH1) is the most severe type, characterized by severe to profound congenital sensorineural hearing loss, vestibular dysfunction, and prepubertal onset of RP eventually leading to legal blindness. USH2 is characterized by moderate to severe hearing impairment, normal vestibular function and later onset of retinal degeneration. USH3 displays progressive hearing loss, RP and variable vestibular phenotype ([@B32]; [@B25]).

Currently, up to 13 genes have been associated with Usher syndrome: *MYO7A*, *USH1C*, *CDH23*, *PCDH15*, *USH1G*, and *CIB2* are responsible for USH1, although the role of *CIB2* in the Usher syndrome has recently been put on doubt ([@B6]). *USH2A*, *ADGRV1*, and *WHRN* are the three genes responsible for USH2, and the *CLRN1* gene is the only one associated with USH3 cases to date. Besides, *PDZD7* has been reported to behave as a modifier of the retinal phenotype in conjunction with *USH2A*, and a contributor to digenic inheritance with *ADGRV1* ([@B11]). In addition, *HARS* was postulated as a novel causative gene of USH3, based on a mutation found in two patients ([@B30]). Finally, mutations in *CEP250* have been reported to cause cone-rod dystrophy, isolated RP and atypical forms of USH, characterized by early onset hearing loss and mild RP ([@B20]; [@B14]; [@B21]).

In the last years, next generation sequencing (NGS) techniques have revolutionized the world of the molecular genetic diagnosis, allowing the whole genome, whole exome and targeted gene sequencing more feasible, and making easier, rapid and cost-effective the identification of disease genes and the underlying mutations. It has been especially useful in genetically heterogeneous diseases, such as hearing loss or retinal dystrophies ([@B7]; [@B13]; [@B26]; [@B16]). We previously developed a targeted next generation sequencing method for Usher syndrome that proved to be highly efficient ([@B1]; [@B14]).

Although the molecular epidemiology of the Usher syndrome and the distribution of mutations causing the disease among these genes has been well studied in Europe and United States, there is a lack of studies in other regions like Africa or Central and South America.

Here, we show for the first time a molecular landscape of the Usher syndrome in Cuba, and we provide as well a clinical description of all the cases.

Materials and Methods {#s1}
=====================

Patients
--------

A descriptive cross-sectional study was carried out in a series of 11 families from Holguin (Cuba) with patients diagnosed clinically as Usher syndrome. All the 11 patients were Caucasian. The family trees of the families are shown in [Figure 1](#F1){ref-type="fig"}.

![Family trees of the Usher families analyzed in this study. Arrows indicate the proband that was studied through the USH targeted panel.](fgene-10-00501-g001){#F1}

The variables collected in this study were: age, sex, ethnicity, birthplace of the patients and their ancestors, consanguinity, age of onset HL and at diagnosis, HL degree, age of the first symptoms of RP and current clinical stage, and vestibular function. The institutional board of both the Ethics Committee of the University Hospital La Fe and the University of Holguín approved the study, according to the tenets of the Declaration of Helsinki and reviews. A survey assessed by the researchers was used in compliance after signing informed consent.

Ophthalmological examination included visual acuity, funduscopy, visual field test with Goldmann perimetry, and electroretinogram (ERG). The Audiological examination consisted of the vestibular function study through the caloric test and study of brainstem auditory evoked potentials (BAEP).

Hearing loss evaluation was carried out using a radio audiometer MA31 (Grosses Klinisches Audiometer, Germany) in the Hospital "Vladimir Ilich Lenin." The BAEPs were obtained in response to the monaural stimulation through TDH-39 hearing aids, with condensation clicks with a duration of 100 μsec and an intensity of 95 dB pSPL. The hearing loss of each affected individual was quantified by performing a complete tonal audiometry. Hearing loss was classified as: Mild (20--40 dB), moderate (40--70 dB), severe (70--90 dB), or profound (more than 90 dB).

Peripheral blood was obtained and DNA was extracted in the National Center for Medical Genetics in Havana, and sent to the University Hospital La Fe in Valencia (Spain).

Targeted Exome Sequencing Design
--------------------------------

We designed a customized AmpliSeq panel using Ion AmpliSeq Designer tool from Thermo Fisher Scientific^[1](#fn01){ref-type="fn"}^ to generate the targeted library composed of all exons contemplated in all isoforms with 10 bp padding of the flanking intron regions, and the additional locus comprising the c.7595-2144A\>G intronic mutation ([@B34]). These target regions were covered by 810 amplicons of 125--175 bp length range, computing a total panel size of 147.95 kb. The designed panel ([Table 1](#T1){ref-type="table"}) included 14 genes, 10 USH causative genes (*MYO7A*, *USH1C*, *CDH23*, *PCDH15*, *USH1G*, *CIB2*, *USH2A*, *ADGRV1*, *WHRN*, and *CLRN1*) and four USH associated genes (*HARS*, *PDZD7*, *CEP250*, and *C2orf71*).

###### 

Details of the target region studied in this study.

  Chr   Gene/locus                     Coding exons   Size (bp)   Number of amplicons   Design coverage
  ----- ------------------------------ -------------- ----------- --------------------- -----------------
  5     *ADGRV1*                       90             20721       181                   99.4%
  1     *USH2A*                        72             17043       134                   98.9%
  10    *CDH23*                        73             11849       120                   99.5%
  10    *PCDH15*                       43             8284        67                    98.2%
  20    *CEP250*                       32             7969        58                    100%
  11    *MYO7A*                        51             7642        88                    98.6%
  2     *C2orf71*                      2              3907        23                    99.6%
  10    *PDZD7*                        17             3474        31                    97.5%
  11    *USH1C*                        29             3334        38                    94.2%
  9     *WHRN*                         14             2964        26                    100%
  5     *HARS*                         15             1790        14                    100%
  17    *USH1G*                        4              1446        12                    100%
  3     *CLRN1*                        9              1051        9                     100%
  15    *CIB2*                         7              684         8                     95%
  1     ^∗^chr1: 216064460-216064620   --             160         1                     100%

Chr, chromosome number.

∗

Region of the USH2A PE (Pseudo-exon 40) where mutation c.7595-2144A\>G is located. Targets are arranged according to the size of the covered region.

Sequence Enrichment and Next Generation Sequencing
--------------------------------------------------

The amplification of the targets was performed according to the Ion AmpliSeq Library Kit 2.0 protocol (Thermo Fisher Scientific, Inc.) for Ion Torrent sequencing. The sequencing was carried out with a theoretical minimum coverage of 500× either on the *PGM* or *Proton* system.

Variant Filtering and Analysis
------------------------------

The resulting sequencing data were analyzed with the Ion Reporter Software tool ^[2](#fn02){ref-type="fn"}^ in regards to the human assembly GRCh37 (also known as hg19). The annotated variants were filtered according to a Minor Allele Frequency (MAF) value ≤0.01, their annotation in the dbSNP^[3](#fn03){ref-type="fn"}^, their description in the Usher syndrome mutation database^[4](#fn04){ref-type="fn"}^ and the mutation type. Those disease-causing and suspected-to-be pathogenic variants were validated through conventional Sanger sequencing. For this, each DNA *locus* comprising a selected mutation was amplified by PCR with specific primers, and both forward and reverse strands were sequenced using the Big Dye 3.1 Terminator Sequencing Kit (Thermo Fisher Scientific, Inc.) after enzymatic PCR clean up with illustra ExoProStar 1-Step (GE Healthcare Life Sciences). The purified sequence products were analyzed on a 3500xL ABI instrument (Applied Biosystems by Thermo Fisher Scientific, Inc.).

The novel variants found in the cohort of probands were categorized based on the guidelines of the *clinical and molecular genetics society*^[5](#fn05){ref-type="fn"}^ and the Unknown Variants classification system (see text footnote 4) as pathogenic, probably pathogenic (UV4), possibly pathogenic (UV3), possibly non-pathogenic (UV2), and neutral (UV1), according to the type of mutation, bioinformatic predictions and segregation analysis. The four novel mutations were frameshift or nonsense mutations. Hence, they were automatically stated as pathogenic variants.

The annotation of the variants was performed according to following isoform reference sequences for each gene: *MYO7A* (NM_000260.3), *USH1C* (NM_153676), *CDH23* (NM_022124.5), *PCDH15* (NM_033056.3), *USH1G* (NM_173477), *CIB2* (NM_006383.2), *USH2A* (NM_206933), *ADGRV1* (NM_032119.3), *WHRN* (NM_015404), *CLRN1* (NM_174878), *HARS* (NM_002109), *PDZD7* (NM_001195263.1), *CEP250* (NM_007186.4), and *C2orf71* (NM_001029883.2).

MLPA Complementary Analysis
---------------------------

In order to ascertain if homozygous mutations could truly be masked cases of a large deletion comprising a heterozygous variant, we performed pertinent multiplex Multiplex ligation-dependent probe amplification (MLPA; MRC-Holland) analysis for the only USH genes available, *USH2A* and *PCDH15*.

###### 

Genetic findings of the patients screened in this study, mutations, their effect on the protein, genes mutated, and nature of the mutations.

  Patient   Diagnosis   Mutations             Effect on protein     Gene     Type of mutation   References
  --------- ----------- --------------------- --------------------- -------- ------------------ ------------
  US-2      USH2        c.15448_15449delCT    p.Leu5150Hisfs^∗^6    ADGRV1   Frameshift         This study
                        c.15448_15449delCT    p.Leu5150Hisfs^∗^6                                
  US-4      USH1        c.4488G\>C            p.Gln1496His          CDH23    Splice site        [@B3]
                        c.7730_7734delTCAGT   p.Phe2577Serfs^∗^28            Frameshift         This study
  US-5      USH1        c.4488G\>C            p.Gln1496His          CDH23    Splice site        [@B3]
                        c.4488G\>C            p.Gln1496His                                      
  US-6      USH1        c.4488G\>C            p.Gln1496His          CDH23    Splice site        [@B3]
                        c.4488G\>C            p.Gln1496His                                      
  US-7      USH1        c.4488G\>C            p.Gln1496His          CDH23    Splice site        [@B3]
                        c.1624G\>T            p.Glu542^∗^                    Nonsense           This study
  US-8      USH?        c.619C\>T             p.Arg207^∗^           CLRN1    Nonsense           [@B15]
                        c.619C\>T             p.Arg207^∗^                                       
  US-9      USH2        c.2299delG            p.Glu767Serfs^∗^21    USH2A    Frameshift         [@B24]
                        c.2299delG            p.Glu767Serfs^∗^21                                
  US-10     USH2        c.3661C\>T            p.Gln1221^∗^          PCDH15   Nonsense           This study
                        c.3661C\>T            p.Gln1221^∗^                                      
  US-11     USH1        c.4488G\>C            p.Gln1496His          CDH23    Splice site        [@B3]
                        c.4488G\>C            p.Gln1496His                                      
  US-12     USH?        c.619C\>T             p.Arg207^∗^           CLRN1    Nonsense           [@B15]
                        c.619C\>T             p.Arg207^∗^                                       
  US-16     USH2        c.1841-2 A\>G         p.Gly614Aspfs^∗^6     USH2A    Splice site        [@B17]
                        c.1841-2 A\>G         p.Gly614Aspfs^∗^6                                 

Results
=======

Eleven index cases diagnosed of Usher syndrome from the province of Holguín, Cuba, were screened for mutations in the USH-associated genes of our home-designed panel.

Details of the genes, number of amplicons or coverage are described in [Table 1](#T1){ref-type="table"}.

Five cases were diagnosed of USH1, whereas four cases were USH2, and two cases were difficult to classify clinically. All the eleven cases were solved and the specific causative mutations can be found in [Table 2](#T2){ref-type="table"}.

Six families were consanguineous (54.5%) and another two were probably consanguineous (18.2%), since the parents come from the same small village. In total, the consanguinity or probable consanguinity in the cohort is over 70%.

Among the USH1 cohort, two pathogenic mutations were found in *CDH23* (US-4, US-5, US-6, US-7, and US-11). In the USH2 cohort, two pathogenic mutations were found in *ADGRV1* (US-2) and *USH2A* (US-16 and US-9), and *PCDH15* (US-10). Regarding the unclassified cases, two mutations were found in *CLRN1* (US-8 and US-12). Patient US-2, who carried the mutation c.15448_15449delCT in homozygosis in the *ADGRV1* gene, carried the additional c.3242G\>A (p.Arg1081Gln) missense mutation in *CDH23* in heterozygous state, which is predicted to probably damaging according to PolyPhen-2 and benign as SIFT and PROVEAN.

Four mutations are reported in this study for the first time, namely c.15448_15449delCT (p.Leu5150Hisfs^∗^6) in *ADGRV1*, c.7730_7734delTCAGT (p.Phe2577Serfs^∗^28) in *CDH23*, c.1624G\>T (p.Glu542^∗^) in *CDH23*, and c.3661C\>T (p.Gln1221^∗^) in *PCDH15*.

Two mutations have been found in several USH alleles in this study. The p.Arg207^∗^ mutation in *CLRN1* was found in homozygous state in two different families, both of them consanguineous. That means 18.2% of the total mutated alleles and 40% among the non-USH1 mutated alleles. Among the USH1 cases, p.Gln1496His accounted for 80% of the USH1 alleles (eight out of 10) and 36.4% of the total USH alleles. All the USH1 patients bear mutations in *CDH23*.

The sequences of each mutation are shown in [Figure 2](#F2){ref-type="fig"}.

![Sanger electropherograms of the mutations detected in this study.](fgene-10-00501-g002){#F2}

MLPA assays in the patients US-9, US-10, and US-16, with homozygous mutations in either *USH2A* or *PCDH15*, revealed no copy number variations.

Clinical Description
--------------------

The clinical features of the 11 index patients are shown in [Table 3](#T3){ref-type="table"}.

### Mutation: c.15448_15449delCT (p.Leu5150Hisfs^∗^6) in *ADGRV1*

Proband of family US-2: The subject comes from a non-consanguineous family (father from Mexico and mother from Cuba) and displays a typical USH2 phenotype. She presented with a postlingual moderate non-progressive HL, no vestibular dysfunction and postpubertal onset of RP. This patient carries the mutation p.Leu5150Hisfs^∗^6 in *ADGRV1* in homozygosis.

### Mutation: c.619C\>T (p.Arg207^∗^) in *CLRN1*

Proband of family US-8: Patient coming from a consanguineous family, harboring the mutation p.Arg207^∗^ in *CLRN1* in homozygous state. She has a postlingual moderate HL with a progression in the last 10 years. This subject is 81 years old and the progression of the HL may be due to age-related hearing impairment. She noticed nyctalopia at 8 years old and the visual field was much reduced by the age of diagnosis. She did not report any balance problems.

Proband of family US-12: Patient carries the p.Arg207^∗^ mutation in *CLRN1* in homozygous state. The family is also consanguineous, since the parents are second cousins. HL is postlingual and severe. RP signs were similar than those of US-8, yet with a later age of onset of symptoms and reduced visual field at age 24. ERG is abolished for this subject. In addition, the delayed walking onset and the reported difficulties in holding the head up as a baby suggest balance dysfunction.

### Mutation: c.1841-2 A\>G (p.Gly614Aspfs^∗^6) in *USH2A*

Proband of family US-16: The subject has a typical *USH2A* phenotype with a moderate postlingual non-progressive HL and typical RP of onset in the puberty.

### Mutation: c.2299delG (p.Glu767Serfs^∗^21) in *USH2A*

Proband of family US-9: The patient harbors the most common mutation in *USH2A* patients of European origin, namely the c2299delG in *USH2A*. She displays a typical USH2 phenotype milder that US-16 with a mild postlingual HL and later onset of RP symptoms.

### Mutation: c.3661C\>T (p.Gln1221^∗^) in *PCDH15*

Proband of family US-10: This patient carries the p.Gln1221^∗^ mutation in *PCDH15* in homozygous state. *PCDH15* is associated to USH1 phenotype, however, this subject displayed postlingual moderate HL, normal vestibular function and relatively late-onset of RP.

### Mutation: c.7730_7734delTCAGT (p.Phe2577Serfs^∗^28) in *CDH23*

Proband of family US-4: The patient is a compound heterozygote for the *CDH23* mutations p.Phe2577Serfs^∗^28 and p.Gln1496His. He displays a typical USH1 phenotype with a prelingual, severe hearing loss RP onset al puberty and vestibular dysfunction.

### Mutation: c.1624G\>T (p.Glu542^∗^) in *CDH23*

Proband of family US-7: Compound heterozygote for the *CDH23* mutations p.Glu542^∗^ and p.Gln1496His. Symptoms are distinctive of typical USH1 phenotype with a prelingual severe HL, early onset of RP and vestibular dysfunction.

### Mutation: c.4488G\>C (p.Gln1496His) in *CDH23*

Besides the compound heterozygotes US-4 and US-7, that carry p.Gln1496His together with other *CDH23* mutations, three more patients carry the mutation in homozygous state, namely those from families US-5, US-6, and US-11. All of them displayed a typical USH1 phenotype.

Discussion
==========

In this work, we report the first study in a cohort of Usher syndrome patients from Cuba. We found a total of eight mutations in 11 cases, four of which are novel (p.Leu5150Hisfs^∗^6 in *ADGRV1*, p.Phe2577Serfs^∗^28 and p.Glu542^∗^ in *CDH23*, and p.Gln1221^∗^ in *PCDH15*).

###### 

Clinical features of the Cuban patients.

  Family   Consanguinity                                Case (age)   Type   Audiological findings                                                        Vestibular function   Ophthalmological findings                                                                                                                                                                                            
  -------- -------------------------------------------- ------------ ------ ---------------------------------------------------------------------------- --------------------- --------------------------- ------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------
  US-2     No                                           III:2 (76)   USH2   Moderate SNHL; postlingual (adolescence); non-progressive                    Normal                8 yo                        14 yo   VF constriction (tunnel vision); pallor of the optic nerve; attenuated vessels; BLSP                                                                                             Altered
  US-4     No                                           II:1 (42)    USH1   Severe SNHL; prelingual                                                      Altered               18 yo                       27 yo   VF constriction (tunnel vision); pallor of the optic nerve; severe thinning of vessels; BLSP                                                                                     Altered
  US-5     No                                           II:5 (58)    USH1   Profound SNHL; prelingual                                                    Altered               9 yo                        21 yo   VF constriction (tunnel vision), right eye more affected; pallor of the optic nerve; thinning of the vessels; retinal and choroidal degeneration; BLSP in the posterior region   Abolished
  US-6     Yes (1st cousins)                            II:2 (43)    USH1   Severe SNHL; prelingual                                                      Altered               7 yo                        10 yo   Early onset RP; total amaurosis, no VF left; waxy pallor of the optic nerve; optic disc drusen; attenuated vessels; BLSP                                                         Abolished
  US-7     Not reported ^∗^1000--2000 population        II:1 (10)    USH1   Severe SNHL; prelingual; cochlear implant                                    Altered               7 yo                        8 yo    VF and VA remain unaffected; mild thinning of the vessels; normal macula; fine colorless particles in the vitreous; few pigment accumulations                                    Altered
  US-8     Yes (1st cousins)                            II:1 (80)    USH?   Moderate SNHL; postlingual (adolescence); progressive in the last 10 years   Normal                10 yo                       16 yo   VF constriction (tunnel vision); low VA; attenuated vessels; pallor of optic nerve; macular edema and cysts; choroidal vascular fibrosis; BLSP                                   Abolished
  US-9     Yes (2nd cousins)                            II:6 (61)    USH2   Mild SNHL; postlingual (adulthood); progressive                              Normal                20 yo                       30 yo   VF constriction (mid-peripheral ring scotoma); attenuated vessels; pallor of optic nerve; BLSP                                                                                   Abolished
  US-10    No                                           II:1 (59)    USH2   Moderate SNHL; postlingual (adolescence); non-progressive                    Normal                19 yo                       28 yo   VF constriction (tunnel vision); thinning and atrophy of                                                                                                                         Abolished
  US-11    Not reported ^∗^500--1000 population         II:1 (41)    USH1   Profound SNHL; prelingual                                                    Altered               9 yo                        10 yo   VF constriction (tunnel vision), right eye more affected; waxy pallor of the optic nerve; macular degeneration, BLSP                                                             Altered
  US-12    Yes (2nd cousins)                            II:3 (47)    USH?   Severe SNHL; prelingual                                                      Altered               18 yo                       17 yo   VF constriction (tunnel vision), pallor of optic nerve; attenuated vessels; BLSP                                                                                                 Abolished
  US-16    Yes, in the third generation (1st cousins)   II:5 (50)    USH2   Moderate SNHL; postlingual (adolescence); non-progressive                    Normal                14 yo                       26 yo   Severe VF reduction; severe thinning of vessels; pallor of optic nerve; BLSP                                                                                                     Abolished

?, unclear USH category; SNHL, sensorineural hearing loss; NB, night blindness; yo, years old; Dx, diagnosis; VF, visual field; VA, visual acuity; ERG, electroretinogram. Asterisk indicates that the parents come from the same town with the specified number of inhabitants.

The presence in homozygosis of p.Gln1221^∗^ in *PCDH15* led to a typical USH2 phenotype with a severe HL of postlingual onset, no vestibular dysfunction and late onset RP, and despite being the causative mutation a nonsense variant. Although it is not common, mutations in genes that usually lead to USH1 and cause a USH2 phenotype, and vice-versa, have been reported ([@B4]; [@B1]; [@B14]).

The mutations c.1841-2A\>G (p.Gly614Asp^∗^fs6) and c.2299delG (p.Glu767Serfs^∗^21) in *USH2A* have been reported many times in the literature as pathogenic in many populations.

Noteworthy, two mutations are recurrent in this study. The c.619C\>T mutation (p.Arg207^∗^) in *CLRN1* was described by García-García et al. and Licastro et al. almost simultaneously in two *a priori* unrelated Spanish families of Basque origin and one family of Italian origin, respectively ([@B15]; [@B23]). This mutation was found in homozygous state in two Cuban families. In the first family reported by García-García et al., the only affected member carried the p.Arg207^∗^ mutation together with p.Tyr63^∗^. The patient displayed bilateral severe progressive sensorineural HL corrected with hearing aids and was a candidate for cochlear implantation. She showed a delay in gait development and a vestibular hyporeflexia and she displayed typical symptoms of RP since young. The onset of her RP was at 9 years old, including night blindness and peripheral visual loss. Fundus ophthalmoscopy showed pigmentary anomalies typical of RP with a visual acuity of 0.4 in both eyes and a rapid progression of the visual loss.

In the second family there were two affected sibs who were compound heterozygotes for p.Arg207^∗^ and p.Ile168Asn. They displayed very discordant phenotypes. One brother had a typical RP and normal speech acquisition and motor milestones. At 13 years old he displayed a progressive bilateral HL that ranged 79--80 dB in the last clinical examination, and the vestibular function was normal. The other brother presented with a typical RP as well, but displayed a prelingual severe HL that required deaf school education.

These findings illustrate the impressive wide spectrum of sensorineural hearing impairment in type and degree, and the high degree of intersubject and intrafamiliar variability due to *CLRN1* mutations, as previously reported ([@B29]).

The other mutation, c.4488G\>C (p.Gln1496His) in *CDH23*, was described by [@B3] in a large Cuban family. That study allowed the identification of the *CDH23* gene as responsible of Usher syndrome type 1. Although c.4488G\>C is a missense mutation (p.Gln1496His), the G\>C change affects the last exon nucleotide and computational predictions and *in vitro* studies support the hypothesis of a splicing alteration leading to a truncated protein ([@B3]).

Additionally, c.4488G\>C has been reported two more times in the literature in two unrelated families of Spanish origin showing a typical USH1 phenotype ([@B2]; [@B28]).

It is noteworthy that the frequency of the mutated genes varies significantly when compared to other countries. In most populations *MYO7A* is the most prevalent gene among USH1 patients accounting for about 50% of the cases, except in some endogamic populations ([@B31]; [@B22]; [@B16]; [@B35]; [@B5]; [@B8]; [@B10]; [@B33]). However, all the USH1 patients in this cohort carry mutations in *CDH23*. Furthermore, c.4488G\>C accounts for 80% of USH1 alleles and no *MYO7A* mutations were detected in the cohort.

No conclusions can be obtained from the USH2 mutation distribution given the small size of the sample. Two out of the three clear USH2 patients are caused by mutations in *USH2A*, whereas the remaining is due to a mutation in *ADGRV1*. Both *USH2A* mutations have been reported many times in the literature, being c.2299delG the most frequent USH2 mutation in populations of European origin ([@B9]).

The frequency of Usher syndrome due to mutations in *CLRN1* in our sample is 18% (two out of 11), considerably higher than the 5% or less in other populations. Usher syndrome resulting from mutations in *CLRN1* is rare except in Finland and among the Ashkenazi jews, and its high frequency among USH3 patients in these populations is due to founder mutations ([@B18]; [@B27]). Here, the apparently high frequency of *CLRN1* is attributable to the presence of another unique mutation that probably has a Spanish origin.

It must be remarked that most of the mutations found in this study are homozygous, yet it could be possible that these were in fact heterozygous variants in concurrence of a large deletion, even when consanguinity is at stake. MLPA could be performed for mutations in *USH2A* and *PCDH15*, but there is no kit available to analyze the other implicated genes *ADGRV1*, *CLRN1*, and *CDH23*.

Segregation analysis would also help to unveil this issue and also to confirm if the compound heterozygous mutations are indeed in trans and, thus, causative of the disease. However, the obtainment of DNA samples of the relatives was not available.

Although the sample size is very small, it is tempting to speculate that the gene frequencies in Cuba are distinct from other populations, mainly due to an "island effect" and genetic drift. Further studies with a larger sample comprising different geographical regions of Cuba are needed to elucidate the real genetic landscape of Usher syndrome in the Cuban population.
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